Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Talpaz

Showing results (31-40 of 263) with videos related to

Pageof 27
Sort By:
Expert Review of Hematology|May 19, 2015
Ruxolitinib for the treatment of patients with polycythemia veraJean-Jacques Kiladjian, Elliott F Winton, Moshe Talpaz, et al.
Annals of Internal Medicine|May 21, 2003
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeuticsRazelle Kurzrock, Hagop M Kantarjian, Brian J Druker, et al.
Blood Advances|April 19, 2024
Lysosomal degradation targets mutant calreticulin and the thrombopoietin receptor in myeloproliferative neoplasmsAmanpreet Kaur, Arunkumar Venkatesan, Malathi Kandarpa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cellsFaye M Johnson, Babita Saigal, Moshe Talpaz, et al.
Cancer|November 25, 2003
Imatinib mesylate causes hypopigmentation in the skinAnne S Tsao, Hagop Kantarjian, Jorge Cortes, et al.
Cancers|September 28, 2023
Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase SignalingSamuel B Reynolds, Kristen Pettit, Malathi Kandarpa, et al.
Hematology. American Society of Hematology. Education Program|November 10, 2001
Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic StrategiesHagop Kantarjian, Junia V. Melo, Sante Tura, et al.
The Journal of Biological Chemistry|June 10, 2003
TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptorTara C Polek, Moshe Talpaz, Bryant G Darnay, et al.
Annals of Internal Medicine|December 21, 2006
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistanceHagop M Kantarjian, Moshe Talpaz, Francis Giles, et al.
Journal of Hematology & Oncology|August 9, 2018
Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 studyMoshe Talpaz, Susan Erickson-Viitanen, Kevin Hou, et al.
Pageof 27

Showing results (31-40 of 263) with videos related to

Sort By:
Pageof 27
Expert Review of Hematology|May 19, 2015
Ruxolitinib for the treatment of patients with polycythemia veraJean-Jacques Kiladjian, Elliott F Winton, Moshe Talpaz, et al.
Annals of Internal Medicine|May 21, 2003
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeuticsRazelle Kurzrock, Hagop M Kantarjian, Brian J Druker, et al.
Blood Advances|April 19, 2024
Lysosomal degradation targets mutant calreticulin and the thrombopoietin receptor in myeloproliferative neoplasmsAmanpreet Kaur, Arunkumar Venkatesan, Malathi Kandarpa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cellsFaye M Johnson, Babita Saigal, Moshe Talpaz, et al.
Cancer|November 25, 2003
Imatinib mesylate causes hypopigmentation in the skinAnne S Tsao, Hagop Kantarjian, Jorge Cortes, et al.
Cancers|September 28, 2023
Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase SignalingSamuel B Reynolds, Kristen Pettit, Malathi Kandarpa, et al.
Hematology. American Society of Hematology. Education Program|November 10, 2001
Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic StrategiesHagop Kantarjian, Junia V. Melo, Sante Tura, et al.
The Journal of Biological Chemistry|June 10, 2003
TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptorTara C Polek, Moshe Talpaz, Bryant G Darnay, et al.
Annals of Internal Medicine|December 21, 2006
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistanceHagop M Kantarjian, Moshe Talpaz, Francis Giles, et al.
Journal of Hematology & Oncology|August 9, 2018
Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 studyMoshe Talpaz, Susan Erickson-Viitanen, Kevin Hou, et al.
Pageof 27